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a b s t r a c t
Previous studies support resorbable biocomposites made of poly(L-lactic acid) (PLA) and b-tricalcium
phosphate (TCP) produced by supercritical gas foaming as a suitable scaffold for tissue engineering.
The present study was undertaken to demonstrate the biocompatibility and osteoconductive properties
of such a scaffold in a large animal cancellous bone model. The biocomposite (PLA/TCP) was compared
with a currently used b-TCP bone substitute (ChronOS™, Dr. Robert Mathys Foundation), representing
a positive control, and empty defects, representing a negative control. Ten defects were created in sheep
cancellous bone, three in the distal femur and two in the proximal tibia of each hind limb, with diameters
of 5 mm and depths of 15 mm. New bone in-growth (osteoconductivity) and biocompatibility were eval-
uated using microcomputed tomography and histology at 2, 4 and 12 months after surgery. The in vivo
study was validated by the positive control (good bone formation with ChronOS™) and the negative con-
trol (no healing with the empty defect). A major finding of this study was incorporation of the biocom-
posite in bone after 12 months. Bone in-growth was observed in the biocomposite scaffold, including its
central part. Despite initial fibrous tissue formation observed at 2 and 4 months, but not at 12 months,
this initial fibrous tissue does not preclude long-term application of the biocomposite, as demonstrated
by its osteointegration after 12 months, as well as the absence of chronic or long-term inflammation at
this time point.
! 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Not all bone losses are similar and correspondingly not every
clinical situation needs the same treatment [1]. In particular, when
load bearing situations are targeted and the quality of the bone is
not optimal for an autograft the surgeon may be tempted to use an
artificial scaffold to fill the bone defect. This situation often arises
during revision of total knee replacement, where significant bone
loss can be found either under the tibial tray or in the femoral part
of the knee implant [2]. Unfortunately, in this case the use of cal-
cium phosphate cement is not suitable for filling the bone defects,
as this material is too brittle to sustain the shocks that will inevi-
tably arise during normal daily activity [3].
An alternative to a ceramic scaffold could be to use porous bior-
esorbable polymers such as poly a-hydroxyacids [4,5]. However,
despite allowing deformation of the scaffold, which is necessary
for application in total knee revision, these polymer scaffolds do
not offer good enough mechanical properties to resist significant
loadings. To overcome this mechanical drawback ceramic–polymer
composites have gained increasing interest [6–8]. In particular, a
biocomposite of controlled porosity combining b-tricalcium phos-
phate (b-TCP) and poly(L-lactic acid) (PLA) was obtained by super-
critical gas foaming [9]. This biocomposite displayed a cellular
microstructure and elastic properties close to human trabecular
bone [10] and was shown in a numerical study to be able to sustain
the load if used as a tibial spacer to fill the bone defect during revi-
sion of total knee replacement [11]. In vivo studies in small ani-
mals have demonstrated the biocompatibility and
osteoconductivity of the biocomposite developed [12]. The results
in small animals such as rodents have to be considered with cau-
tion if we want to extrapolate them to clinical applications and
need, at least, to be confirmed by studies in large animals. The
sheep is often chosen as an experimental animal because its bone
structure and bone remodelling rate are very similar to those of
humans [13].
The aim of this study was to demonstrate the biocompatibility
and osteoconductive properties of the new PLA/b-TCP biocompos-
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ite in a large animal model over a period of 2, 4 and 12 months and
to determine new bone formation, implant degradation and
inflammation compared with an untreated (empty) control. A po-
sitive control, made of porous b-TCP, already used clinically as a
bone substitute (ChronOS™), was also included in the study.
2. Materials and methods
2.1. Scaffold
Manufacture of the new PLA/b-TCP biocomposite and character-
ization of its morphology and material properties have been de-
scribed previously [10]. Briefly, the biocomposite is obtained by a
two steps process, namely melt extrusion and supercritical CO2
foaming. PLA granules (Boehringer Ingelheim) and b-TCP powder
(Dr. Robert Mathys Foundation) are first dried to avoid polymer
degradation. Both raw materials, in a 95/5 wt.% PLA/b-TCP ratio,
are mixed and melt extruded in a micro-extrudor (Micro 5 DSM).
The composite rods obtained are then cut, dried again, put into a
mould and placed in a high pressure and temperature chamber
(Autoclave France). The pressure is increased to 225 bar at which
pressure PLA melted at 195 "C. Porosity was then created by CO2
release and control of the depressurisation and cooling rates.
The positive control used in this study, ChronOS™ (Dr. Robert
Mathys Foundation), is an established bone substitute. ChronOS™
consists of pure b-TCP and was obtained using the calcium phos-
phate emulsion method [14]. Briefly, a hydrophobic liquid is mixed
with calcium phosphate paste and an emulsifier. After mechanical
stirring an oil/cement paste emulsion is prepared. Once the cement
has set and after oil washing porous ceramic blocks are then ob-
tained. Finally, sintering at 1250 "C leads to porous b-TCP blocks.
Both types of material, biocomposite and ChronOS™, were then
machined to obtain 15 mm long by 5 mm diameter cylinders. All
scaffolds were sterilized by c-irradiation before implantation.
2.2. Animal study
The animal model considered in this study has been described
by Zeiter et al. [15]. All animal experiments were performed with
the approval of the Veterinary Authority of the Canton Graubünden
(no. 16/2006).
Briefly, 13 female Swiss Alpine sheep, with a mean age of
3 years and a mean weight of 50 kg, were used. Two custom made
jigs, one with three holes and one with two holes, were used to po-
sition the defects in cancellous bone in the femur and tibia, respec-
tively, in a standardized way. Three defects with a diameter of
5.1 mm were drilled in the distal part of both femora and two in
the proximal part of both tibiae (bilateral model), cleaned with sal-
ine solution to remove osseous drilling particles and implanted
with a scaffold or left empty. In each femur there was a defect filled
with the biocomposite (Fig. 1), a defect filled with ChronOS™ as
positive control and one defect left empty as a negative control.
In the left tibia one defect was filled with the biocomposite and
the other with ChronOS™. In the right tibia one defect was filled
with the biocomposite and one left empty as a negative control.
The site of the scaffolds within each bone was evenly distributed
between animals to avoid a location bias. Small screws were also
inserted in order to correctly position the removal jig at
explantation.
Animals were killeded euthanized after 2, 4 and 12 months (4
animals per time point). After positioning of the custom made re-
moval jig with the aid of the positioning screws, implants were
harvested using a coring device (trephine attachment, Synthes)
with an outer diameter of 12.5 mm. The resulting core consisted
of the implant/defect in the centre with approximately 3 mm of
surrounding cancellous bone. Samples were analysed by micro-
CT and histology.
2.3. Blood analysis
Blood was taken from each animal before surgery, 1 week and
2 weeks after surgery as well as before being killed euthanized.
The total number of white blood cells and the differential blood
count were determined.
2.4. Micro-CT
The harvested cores were fixed in 70% ethanol for 3 days prior
to micro-CT analysis (lCT 40, Scanco Medical). The long axis of
the bone samples was aligned orthogonally to the axis of the X-
ray beam and a 5 mm region of interest in the middle of the sample
was measured, representing the created defect. In that region bone
volume to total volume (BV:TV) was evaluated by thresholding.
Additionally three-dimensional (3D) reconstructions of the region
of interest were created.
A measurement protocol was created to define the scanning
parameters, including a source voltage of 70 kV and intensity
114 lA. The scans were performed using high resolution settings.
Each scan yielded an image data set of 400 slices. The resulting
two-dimensional images had an element size of 18 lm in all three
spatial dimensions. A 3D Gaussian filter with r = 0.8 and a support
of one voxel was used to partially suppress noise.
2.5. Histology
Samples were dehydrated in an ascending series of alcohol (50–
100%) and defatted with xylene. After infiltration of the samples
with liquid LR-white in an evacuated container at 4 "C for 14 days
they were polymerized with LR-white into ready to cut sample
blocks. A circular saw (Leitz 1600 Saw microtome, Leica) was used
to cut 200 lm thick cross-sections in the middle of the harvested
core.
Macroradiographs (Faxitron X-Ray System, Hewlett Packard)
were taken from each cross-section before further preparation of
the samples. The sections were then ground and polished down
to 80–100 lm thick sections (Exact Micro Grinding System, Exakt
Apparatebau). Their surface was etched with 1% formic acid (Fluka)
for 30 s, rinsed, stained with 1% Toluidine blue (Fluka) for 20 min
and blot dried after washing in deionized water. Further, as a sec-
Fig. 1. Medial view of the distal femur. The defects were flushed with lactate
Ringer’s solution prior to inserting the implants in a drilled defect of 5.1 mm
diameter and 15 mm depth.
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ond stain Giemsa–eosin was used. Sections were stained in eosin
solution for 20 min and in Giemsa solution for !3 min.
All stained sections were evaluated qualitatively for new bone
formation, implant integration and degradation, as well as signs
of inflammation and/or immunological reaction.
2.6. Histomorphometry
For quantitative analysis microradiographs were digitized. Rel-
ative bone formation within the bone defect was assessed as area
of high density (bone) vs. area of low density (soft tissue) by thres-
holding images using a custom made macro (KS400 v. 3.0, Zeiss)
(Fig. 2).
2.7. Statistics
All results are given as means ± standard deviations.
3. Results
3.1. Surgeries
All surgeries were performed without complications and all
samples were introduced into the defects according to the study
plan. Animals recovered well from surgery and showed no signs
of lameness. One sheep developed pneumonia after 1 month and
had to be excluded from the study. This sheep was replaced.
3.2. Blood analysis
Total leukocytes counts and the differential blood analysis were
within the physiological range for all sheep of all groups during the
study.
3.3. Micro-CT
The bone volume to total volume ratio (BV:TV) is presented in
Fig. 3. In defects treated with the biocomposite BV:TV increased
from 1.8 ± 1.1% at 2 months, to 3 ± 1.6% at 4 months, and to
22.4 ± 12.3% at 12 months. In the empty defects after 2 months
the BV:TV was 6.1 ± 3.4% and healing continued after 4 months,
resulting in a BV:TV in the defect area of 13.7 ± 13% at 4 months
and 16.7 ± 9.9% at 12 months. In the defects filled with ChronOS™
the BV:TV was higher, between 40 and 50% at all time points. How-
ever, the thresholding was difficult to establish with the b-TCP
scaffold as this scaffold responds to micro-CT in the same way as
bone hydroxyapatite.
Representative 3D reconstructions of the empty (top) and the
biocomposite (bottom) filled defects at 4 months (left) and
12 months (right) are presented in Fig. 4. The treated defect with
the biocomposite scaffold showed new bone formation after
4 months at the edges of the defect. The amount of new bone in-
creased with time and the whole volume was filled with newly
formed bone with a trabecular structure at 12 months. The empty
defect showed dense ring formation from the edge of the defect to-
wards the centre, thickening from 2 to 12 months.
Fig. 2. Microradiographs of two defects (left, empty; right, biocomposite) with different extents of bone in-growth at 12 months.
Fig. 3. Micro-CT evaluation. Bone volume to total volume (BV:TV) within the defect area at 2, 4 and 12 months.
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3.4. Histology and histomorphometry
New bone formation within the defect area was dependent on
the treatment and time point.
3.4.1. Biocomposite
At 2 months voids within the biocomposite were filled with an
amorphous substance and only a few new bone islands were seen,
mainly at the edge of the defect. These bony islands were separated
from the biocomposite by a fibrous layer. Around the bone substi-
tute some large foreign body cells and multi-nucleated giant cells
were observed. Additionally, a few sporadic inflammatory cells
were detected on the outside area of the implant. A bone density
of 10.2 ± 3.7% was observed in the biocomposite after 2 months.
At 4 months new bone formation within the defect had increased
slightly to a bone density of 12.6 ± 3.4%. The fibrous tissue layer be-
tween implant material and newly formed bone was still visible.
Several accumulations of macrophages and foreign body cells were
still visible, with mild and local inflammation signs present. At
12 months the bone density within the biocomposite had in-
creased to 29.4 ± 4.8%. In all samples new bone was detected in
the central region of the biocomposite. In contrast to the 2 and
4 months results, no fibrous tissue encapsulation or inflammatory
cells were observed. Although the scaffold material was still visible
in the defect area, the amount had decreased remarkably com-
pared with the earlier time points (for representative images see
Fig. 5).
3.4.2. Empty defect
Remains of haemosiderin and fibrous material were noticed at 2
and 4 months in the centre of the defect. There was a continuing
increase in bone density within the defect from 12.9 ± 2.2% at
2 months to 26.9 ± 6.4% at 4 months. At 12 months 28.4 ± 15.3%
of the defect was filled with newly formed bone. This bone was
formed mainly at the edge of the defect and its structure was den-
ser than the surrounding trabecular bone (for representative
images see Fig. 6). No inflammatory cells were observed at any
time points.
3.4.3. ChronOS™
Histological analysis revealed good integration of the implant in
the bone structure at all time points. The granules of ChronOS™
were incorporated into newly formed bone. At 2 months granules
were still clearly detectable in the centre of the defect. The bone
density was at that time point 31.9 ± 8.0%, which increased to
38.5 ± 9.8% at 4 months. By then newly formed bone was noticed
even in the centre of the defect area and new trabeculae were
formed between adjacent bone and the newly formed bone. Osteo-
clasts were detected as a sign of ongoing remodelling. Empty tra-
becular spaces were refilled with non-reactive bone marrow. At
12 months some granules were still visible, but new bone forma-
tion prevailed in the defect area. At this time point 40.5 ± 12.3%
of the defect was filled with bone (for representative images see
Fig. 7).
4. Discussion
A biocomposite scaffold made of PLA/b-TCP was tested in vivo
in sheep femur and tibia up to 12 months in a bilateral model. This
new bone substitute was compared with a negative control (defect
left empty) and a positive control (b-TCP scaffold ChronOS™).
Fig. 4. Representative 3D reconstructions of CT scans of the empty defect (top) and the defect treated with the biocomposite (bottom) at 4 (left) and 12 months (right). Scale
bar 1 mm.
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A major finding of this study was incorporation of the biocom-
posite into bone after 12 months. Bone in-growth was observed in
the biocomposite scaffold, including its central part. This is an
important result as it has been mentioned that scaffolds often fail
to support viable tissue in their interior, as shown in many in vitro
studies [16]. Micro-CT scans presented a nice contrast between
bone and polymer, thus allowing good visualization of bone in-
growth in biocomposite filled defects and ones left empty. Bone
in-growth in those defects was slow in both cases and bone grew
from the outside towards the inside of the defect. A similar trend
was observed when the biocomposite was implanted in rat cranial
defect and knee condyle models [17]. New bone formation and
morphology differed between the empty and biocomposite groups:
in the defects left empty new bone grew as a dense structure,
forming a dense ring on the outer diameter of the defect, whereas
a more trabecular like structure was obtained in the presence of
the biocomposite at 12 months. The biocomposite served as a sup-
port for the formation of new bone: cells were guided by the scaf-
fold structure to generate new bone. This structure was missing in
the defect left empty, where cells grew layer by layer, forming a
dense ring.
Porous PLA scaffolds have usually been combined with osteo-
genic factors such as cells [17,18] or growth factors [19]. In the
present study the bone in-growth observed at 12 months was
exclusively due to the osteoconductive properties of the biocom-
posite. The presence of b-TCP particles in the biocomposite cer-
tainly plays a positive role in the observed bone in-growth.
The effect of the b-TCP particles has been specifically high-
lighted in a rabbit study, in which a clear correlation between
the percentage of b-TCP particles incorporated in a PLA scaffold
and bone healing was established [20]. A 40/60 wt.% PLA/b-TCP ra-
tio showed the best results. Indeed, the positive effect of b-TCP on
bone healing and on the absence of fibrous tissue was also demon-
strated in the present study with the ChronOS™ scaffold. As early
as 2 months good osteointegration of this scaffold was observed. It
could then be advantageous to increase the amount of b-TCP in the
developed biocomposite, which actually presents a 95/5 wt.% PLA/
b-TCP ratio. However, due to processing of the biocomposite by
super critical CO2 foaming, 5 wt.% filler content was shown to be
the upper limit to obtain a homogeneous and interconnected cellu-
lar architecture [10]. In addition, increasing the amount of b-TCP,
would make the biocomposite more brittle and it would lose its
ability to sustain any deformation.
It is interesting to note that if the study had been terminated
after 4 months a negative conclusion would have been drawn, as
fibrous tissue was still present at this time point. At 12 months
no fibrous tissue could be found. The presence of fibrous tissue
at early time points is the consequence of an inflammatory reac-
Fig. 5. Representative histological sections (left, overview, scale bar 1 mm; right, detail, scale bar 200 lm) from defects treated with the biocomposite at 2 (top), 4 (middle)
and 12 months (bottom). The interface between biocomposite and bone is indicated by an arrow. A fibrous tissue layer separates the biocomposite and bone at 2 and
4 months, whereas at 12 months direct bone contact is observed.
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tion due to the presence of the scaffold. It has been reported that
polymer scaffolds such as PLA may induce an inflammatory reac-
tion, as this polymer releases lactic acid during its degradation
[21]. It is the accumulation of this acid which becomes toxic
[22]. The initial fibrous tissue formation observed in this study
has been previously reported with PLA implants inserted into rab-
bits [20]. However, this fibrous tissue does not always disappear
and may be present after more than 6 months [20,23,24]. The ab-
sence of fibrous tissue at 12 months in our study may be related
to the presence of the b-TCP particles, as b-TCP has been shown
to decrease the inflammatory reaction when composite PLA/b-
TCP scaffolds were implanted [20]. Indeed, in the present study
most of the b-TCP particles were embedded in the PLA trabecula
of the biocomposite scaffold, as was seen in a previous study
[10]. These particles will be released and will positively influence
biocomposite osteointegration only after degradation of the PLA
has occurred. This process may explain why fibrous tissue was ob-
served at 2 and 4 months but not at 12 months. To accelerate
osteointegration of the biocomposite it could be advantageous to
control the distribution of b-TCP particles in the PLA in order that
some of them are on the surface of the PLA, not only embedded.
The degradation rate of the biocomposite was slow compared
with the ChronOS™ scaffold. Even if the degradation rate of PLA,
which is driven by a hydrolysis process, can be modulated by con-
trolling its crystallinity [25] or morphology [26], to mention only
two possibilities, the relatively slow degradation rate is common
to many PLA materials. In this study the amount of biocomposite
had decreased remarkably at 12 months compared with the earlier
time points. A longer experiment would then be necessary to
ascertain that no adverse effects would be found before complete
degradation of the biocomposite. However, clinical studies using
PLA materials demonstrate excellent incorporation, even in the
slow degradation rate situation. For example, in a clinical applica-
tion where PLA screws were used to fix a patellar tendon graft for
anterior cruciate ligament replacement after 30 months the PLA
screws were not completely degraded, while no inflammation
was observed [27]. In a lumbar fusion application PLA cages were
used in goats and followed for 48 months. At this time point no
PLA was found in most of the animals treated and no inflammation
was observed [28].
The degradation rate obviously should depend on the clinical
applications targeted. In situations where the scaffold will play
an important mechanical role the degradation rate should not be
too fast to allow new bone formation to take over the mechanical
load. The relatively slow rate of degradation of the biocomposite
would then not be an inconvenience, as the scaffold would need
to sustain the mechanical load in a situation such as that prevailing
in total knee replacement. Slow degradation of the scaffold would
Fig. 6. Representative histological sections (left, overview, scale bar 1 mm; right, detail, scale bar 200 lm) from defects left empty at 2 (top), 4 (middle) and 12 months
(bottom). New bone formation was mainly seen at the border of the defect and newly formed bone was much denser than the trabecular structure surrounding the defect.
3760 U. van der Pol et al. / Acta Biomaterialia 6 (2010) 3755–3762
then provide more certainty that the bone would have enough
time to colonize the biocomposite, achieving the mechanical prop-
erties required to sustain the load [11].
The goal of this study was not to place calcium phosphate scaf-
folds such as ChronOS™ in competition with the developed bio-
composite. Calcium phosphate scaffolds have been successful for
several clinical applications [29] and were thus used in this study
as a positive control for the in vivo model. As already mentioned,
calcium phosphate scaffolds cannot sustain shock due to their brit-
tle nature, rendering their use difficult in, for example, filling bone
defects during total knee revision. For this particular application,
based on a numerical study, we determined that the biocomposite
could sustain a 1% deformation [11], due to its ductile behavior.
This 1% deformation was recently demonstrated to increase bone
formation during an in vivo study performed in rats [30]. Clearly,
the biocomposite developed here is complementary to calcium
phosphate scaffolds and could be used for clinical applications
for which calcium phosphate scaffolds are not suitable. It should
also be mentioned that the biocomposite scaffold allowed the
use of screws, which is a complementary advantage compared
with calcium phosphate scaffolds.
In conclusion, the developed biocomposite scaffold presented
good results at 12 months in sheep, with no inflammation and slow
but constant bone in-growth along the support, with the formation
of new bone of trabecular structure. Due to its ductile behavior
[10], the biocomposite could find application in load bearing situ-
ations, such as in bone filling during revision of total knee
arthroplasty.
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Appendix A. Figures with essential colour discrimination
Certain figures in this article, particularly Figures 2–7, are diffi-
cult to interpret in black and white. The full colour images can be
found in the on-line version, at doi:10.1016/j.actbio.2010.03.028).
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